文献速递肾小球疾病

基于血清学方法管理膜性肾病的提议

A Proposal for a Serology-Based Approach to Membranous Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2016-10-24

本文提出基于血清学的个体化方法管理原发性膜性肾病,以补充和优化传统以蛋白尿为导向的策略。抗PLA2R抗体水平与疾病活动度密切相关,低基线且下降预示自发缓解,高基线或上升提示需及时免疫抑制治疗;抗体再现或升高先于临床复发,肾移植后持续或再现预示复发。

要点

  • 抗PLA2R和抗THSD7A抗体可辅助鉴别原发性与继发性膜性肾病。
  • 低基线且下降的抗PLA2R抗体强烈预测自发缓解,支持保守治疗。
  • 高基线或上升的抗PLA2R抗体与肾病综合征及肾功能进展相关,鼓励及时免疫抑制治疗。

核心结论

  • 作者提出基于血清学的个体化方法管理膜性肾病,补充和优化传统以蛋白尿为导向的方法,有望改善疾病结局。

研究设计与样本

  • 本文为提议性文章,未报告系统检索范围或样本量。

主要发现

  • 抗PLA2R和抗THSD7A抗体的存在与否为鉴别原发性与继发性膜性肾病提供重要信息。
  • 抗PLA2R抗体水平及可能的抗THSD7A抗体水平与疾病活动度紧密相关。
  • 低基线且下降的抗PLA2R抗体强烈预测自发缓解,支持保守治疗。
  • 高基线或上升的抗PLA2R抗体与肾病综合征及肾功能进行性丧失相关,鼓励及时启动免疫抑制治疗。
  • 血清抗PLA2R抗体谱可靠预测治疗反应,治疗完成时水平可能预测长期结局;抗体滴度再现或升高先于临床复发;肾移植后抗PLA2R抗体持续或再现预测复发。

临床怎么用

  • 作者提出基于血清学的个体化方法管理膜性肾病,以补充和优化传统以蛋白尿为导向的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies against the recently discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Assays for quantitative assessment of anti-PLA2R antibodies are commercially available, but a semiquantitative test to detect anti-THSD7A antibodies has been only recently developed. The presence or absence of anti-PLA2R and anti-THSD7A antibodies adds important information to clinical and immunopathologic data in discriminating between primary and secondary MN. Levels of anti-PLA2R antibodies and possibly, anti-THSD7A antibodies tightly correlate with disease activity. Low baseline and decreasing anti-PLA2R antibody levels strongly predict spontaneous remission, thus favoring conservative therapy. Conversely, high baseline or increasing anti-PLA2R antibody levels associate with nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation of immunosuppressive therapy. Serum anti-PLA2R antibody profiles reliably predict response to therapy, and levels at completion of therapy may forecast long-term outcome. Re-emergence of or increase in antibody titers precedes a clinical relapse. Persistence or reappearance of anti-PLA2R antibodies after kidney transplant predicts development of recurrent disease. We propose that an individualized serology-based approach to MN, used to complement and refine the traditional proteinuria-driven approach, will improve the outcome in this disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. De Vriese AS, Glassock RJ, Nath KA, et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2016. PMID: 27777266. doi:10.1681/ASN.2016070776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。